Ray Therapeutics RTx-015 Receives EMA PRIME Designation for Retinitis Pigmentosa Treatment

Key Takeaways

• EMA grants PRIME designation to Ray Therapeutics’ RTx-015 gene therapy for retinitis pigmentosa treatment
• PRIME status provides accelerated regulatory pathway and enhanced EMA support for clinical development
• RTx-015 represents potential breakthrough therapy for patients with severe retinal degeneration causing vision loss

---

Ray Therapeutics announced today that the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to RTx-015, the company’s lead gene therapy candidate for treating retinitis pigmentosa (RP).

The Berkeley, California-based clinical-stage biopharmaceutical company is developing RTx-015 as a differentiated vision restoration therapy for patients living with severe retinal degenerations. PRIME designation is reserved for medicines that address unmet medical needs and show potential to benefit patients significantly.

Regulatory Pathway Acceleration

PRIME designation provides Ray Therapeutics with enhanced regulatory support from the EMA throughout RTx-015’s clinical development. This includes early and proactive dialogue with regulators, accelerated assessment timelines, and dedicated scientific advice to optimize the drug’s path to market approval.

Retinitis pigmentosa affects approximately 1 in 4,000 people worldwide, causing progressive vision loss through photoreceptor cell degeneration in the retina. Current treatment options remain limited, creating significant unmet medical need for effective therapies.

Gene Therapy Innovation

RTx-015 represents Ray Therapeutics’ approach to vision restoration through gene therapy technology. The treatment aims to address the underlying genetic causes of retinal degeneration rather than merely managing symptoms.

The PRIME designation follows Ray Therapeutics’ broader clinical development strategy for RTx-015, positioning the company to advance through regulatory milestones more efficiently. This regulatory recognition validates the therapeutic potential of RTx-015 in addressing a condition with few viable treatment alternatives.

Market Impact

The designation strengthens Ray Therapeutics’ competitive position in the retinal gene therapy market. With PRIME status, the company gains regulatory advantages that could accelerate time-to-market and reduce development risks associated with bringing innovative therapies to patients with rare retinal diseases.

For patients with retinitis pigmentosa, this development represents progress toward potentially transformative treatment options that could preserve or restore vision function.

---

Frequently Asked Questions

What does PRIME designation mean for RTx-015 development?

PRIME designation provides Ray Therapeutics with accelerated regulatory pathways, enhanced EMA scientific advice, and dedicated support throughout clinical development, potentially reducing time to market approval.

When will RTx-015 be available to patients?

RTx-015 is currently in clinical development. While PRIME designation accelerates the regulatory process, the therapy must complete clinical trials and receive marketing authorization before becoming available to patients.

How does RTx-015 differ from existing retinitis pigmentosa treatments?

RTx-015 is a gene therapy designed to address underlying genetic causes of retinal degeneration, potentially offering vision restoration rather than symptom management, representing a novel approach compared to current limited treatment options.